BFRI
Biofrontera Inc

8,746
Mkt Cap
$9.42M
Volume
69,190.00
52W High
$1.87
52W Low
$0.536
PE Ratio
-0.45
BFRI Fundamentals
Price
$0.7401
Prev Close
$0.809
Open
$0.771
50D MA
$0.9821
Beta
0.58
Avg. Volume
97,011.39
EPS (Annual)
-$3.22
P/B
-3.65
Rev/Employee
$401,301.08
Loading...
Loading...
News
all
press releases
Biofrontera Earnings Preview
read more...
Benzinga·9d ago
News Placeholder
More News
News Placeholder
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -3.70% and -75.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of +3.33% and +16.60%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +58.54% and +50.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +116.81% and +20.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of +50.00% and +75.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +27.78% and +9.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -45.45% and +9.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates
Zacks·6mo ago
News Placeholder
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
chainwire·7mo ago

Latest BFRI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.